Vyne Therapeutics Inc
VYNE0.557USD
-0.002-0.38%
收盘 02/09, 16:00（美东）报价延迟15分钟
169.79K总市值
亏损市盈率 TTM
关于 Vyne Therapeutics Inc 公司
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc简介
公司代码VYNE
公司名称Vyne Therapeutics Inc
上市日期Jan 25, 2018
CEODomzalski (David)
员工数量13
证券类型Ordinary Share
年结日Jan 25
公司地址685 Route 202/206 N., Suite 301
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08807
电话18007757936
网址https://vynetherapeutics.com/
公司代码VYNE
上市日期Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7858.00%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
51.16K
-3579.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
41.85K
-2448.00%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7858.00%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
51.16K
-3579.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
41.85K
-2448.00%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2024
FY2023
FY2022
FY2021
FY2020
业务USD
名称
营收
占比
Royalty revenues
501.00K
0.00%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Royalty revenues
501.00K
0.00%
股东统计
更新时间: 2月7日 周六
更新时间: 2月7日 周六
持股股东
股东类型
持股股东
持股股东
占比
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
其他
88.75%
持股股东
持股股东
占比
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
其他
88.75%
股东类型
持股股东
占比
Hedge Fund
8.46%
Investment Advisor
3.54%
Corporation
3.35%
Investment Advisor/Hedge Fund
2.27%
Individual Investor
1.23%
Research Firm
0.45%
其他
80.70%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
88
4.87M
14.64%
-6.85M
2025Q3
84
8.51M
25.77%
-898.65K
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Access Industries, Inc.
1.12M
3.35%
--
--
Oct 15, 2025
Baker Bros. Advisors LP
851.35K
2.56%
+851.35K
--
Sep 30, 2025
Delaware Street Capital, L.L.C.
696.47K
2.09%
--
--
Sep 30, 2024
Acorn Capital Advisors, LLC
586.57K
1.76%
-150.00K
-20.36%
Sep 30, 2025
Shay Capital LLC
492.58K
1.48%
+492.58K
--
Sep 30, 2025
Acadian Asset Management LLC
446.41K
1.34%
+424.00K
+1891.32%
Sep 30, 2025
The Vanguard Group, Inc.
190.38K
0.57%
-305.91K
-61.64%
Sep 30, 2025
Ikarian Capital LLC
290.00K
0.87%
--
--
Sep 30, 2025
Two Sigma Investments, LP
277.39K
0.83%
+277.39K
--
Sep 30, 2025
Domzalski (David T)
152.86K
0.46%
-12.68K
-7.66%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
公告日期
除权除息日
类型
比率
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
